

August 15, 2024

Press Release

TOWA PHARMACEUTICAL CO., LTD.

## **Acquired approval for manufacturing and marketing generic drugs**

Towa Pharmaceutical Co., Ltd. (Head office: Kadoma, Osaka; President and Representative Director: Itsuro Yoshida) has been granted manufacturing and marketing approval for the following six ingredients and ten items of generics today.

Of these six ingredients, RIVAROXABAN and VILDAGLIPTIN are the first to be approved as generic drugs.

<<Products for which manufacturing and marketing approval has been granted>>

### 1. RIVAROXABAN OD TABLETS

Product name	RIVAROXABAN OD TABLETS 10mg “TOWA” / OD TABLETS 15mg “TOWA”
Brand-name drugs	Xarelto OD tablets 15mg

### 2. VILDAGLIPTIN TABLETS

Product name	VILDAGLIPTIN TABLETS 50mg “TOWA”
Brand-name drugs	Equa Tablets 50mg

### 3. LENALIDOMIDE CAPSULES

Product name	LENALIDOMIDE CAPSULES 2.5mg “TOWA” / CAPSULES 5mg “TOWA”
Brand-name drugs	Revlimid Capsules 2.5mg

### 4. SUGAMMADEX INTRAVENOUS SOLUTION

Product name	SUGAMMADEX INTRAVENOUS SOLUTION 200mg “TOWA” / INTRAVENOUS SOLUTION 500mg “TOWA”
Brand-name drugs	BRIDION Intravenous 200mg / 500mg

### 5. SUMATRIPTAN TABLETS

Product name	SUMATRIPTAN TABLETS 50mg “TW”
Brand-name drugs	IMIGRAN Tablets 50

### 6. LOXOPROFEN SODIUM TAPE

Product name	LOXOPROFEN SODIUM TAPE 50mg “TW”/ TAPE 100mg “TW”
Brand-name drugs	LOXONIN TAPE 100mg

[Inquiries]

Public Relations and Investor Relations Department, Towa Pharmaceutical Co., Ltd.

2-11 Shinbashi-cho, Kadoma, Osaka 571-8580, Japan

Tel: +81-6-6900-9102 / Email: kouhou@towayakuhin.co.jp